GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with the Schall Law Firm

GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Investors who purchased the Company’s securities between May 13, 2025 and February 19, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before August 4, 2026. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Grail misled investors about the prospects of its NHS-Galleri trial in reducing Stage III-IV cancers, concealing adverse facts from the trial while describing it positively. The Company’s optimism related to the NHS-Galleri study was overstated, and ignored data suggesting its three-year timeframe was insufficient to demonstrate the successful achievement of the study’s primary endpoint. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Grail, investors suffered damages. Join the case to recover your losses.